Novavax, a vaccine development company headquartered in Gaithersburg, has initiated Phase 3 for its COVID-19 vaccine candidate.
It is the fifth candidate to reach Phase 3 in the U.S., after Pfizer, Moderna, AstraZeneca and Janssen. Novavax is looking for volunteers to participate in vaccine trials, particularly those who are part of at-risk populations like Hispanics, African Americans, older adults and those with underlying medical conditions.
MyMCM spoke with Dr. Gregory Glenn, President of Research and Development at Novavax, about the trial process. He strongly encourages people to volunteer.
Glenn said Novavax could complete Phase 3 this spring. The company plans to obtain Emergency Use Authorization (EUA) from the FDA, like Pfizer and Moderna. Those interested in volunteering for vaccine trials can find out if they’re eligible and learn more here. There are two local trial sites: the University of Maryland and Howard University, Glenn said.
